greeksoup/ stock research
Stock research / United States / MMED / Q3 FY2025

MiniMed Group (MMED) Q3 FY2025 earnings: revenue $687 million

MiniMed Group, Inc. (MMED) reported revenue of $687 million for Q3 FY2025, the quarter ended 24 January 2025. Net income was -$10 million, and diluted earnings per share $-0.04. The figures are the company's own, from the 10-Q it filed with the SEC on 17 April 2026.

Revenue$687 million
Net income-$10 million
Diluted EPS$-0.04
QuarterQ3 FY2025ended 24 January 2025

The quarter, against the one before and a year earlier

LineQ3 FY2025Quarter beforeA year earlierChange on the year
Revenue687n/an/an/a
Cost of revenue292n/an/an/a
Gross profit395n/an/an/a
Gross margin57.5%n/an/a
Research and development112n/an/an/a
Selling, general and administrative268n/an/an/a
Operating income21.0n/an/an/a
Operating margin3.1%n/an/a
Pre-tax income21.0n/an/an/a
Income tax28.0n/an/an/a
Effective tax rate133.3%n/an/a
Net income-10.0n/an/an/a
Net margin-1.5%n/an/a
Diluted EPS-$0.04n/an/an/a
$ million except per share.
Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.

Cash flow and capital returned

LineQ3 FY2025Quarter beforeA year earlierChange on the year
Share-based compensation11.0n/an/an/a
Diluted shares, weighted253mn/an/an/a
Shares outstanding at period end281mn/an/an/a

Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.

Balance sheet at quarter end

LineQ3 FY2025Quarter beforeA year earlierChange on the year
Shareholders' equity3,485n/an/an/a
Cash and equivalents10.0n/an/an/a

Questions

What was MiniMed Group's revenue in Q3 FY2025?

MiniMed Group (MMED) reported revenue of $687 million for Q3 FY2025, the quarter ended 24 January 2025.

How much did MiniMed Group earn in Q3 FY2025?

Net loss for Q3 FY2025 was $10 million, and the diluted loss per share $0.04.

When did MiniMed Group report Q3 FY2025 results?

MiniMed Group filed its 10-Q for the quarter ended 24 January 2025 with the SEC on 17 April 2026.

Quarterly results, the last 4 quarters

Q3 FY2025Q1 FY2026Q3 FY2026Q1 FY2027
Revenue687723790843
Cost of revenue292314428378
Gross profit395409362465
Gross margin57%57%46%55%
R&D112125114115
SG&A268283309312
Operating income21.0-13.0-1005.0
Operating margin3%-2%-13%1%
Pre-tax income21.0-13.0-99.04.0
Tax rate133%n/an/a100%
Net income-10.0-19.0-1190.0
Net margin-1%-3%-15%0%
Diluted EPS-$0.04-$0.08-$0.47$0.00
Operating cash flown/a-141n/a-49.0
Capital expendituren/a53.0n/a41.0
Free cash flown/a-194n/a-90.0
Shares outstanding281m281m281m281m
Filing10-Q10-Q10-Q10-Q
Each quarter as filed, linked to its filing.
Read moreMoney is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

10-Q for the period ended 24 January 2025, filed 17 April 2026: the filing.